分子检测在临床环境中诊断血流感染的性能:系统文献综述与荟萃分析
该系统综述与荟萃分析评估了阳性血培养物分子检测在临床环境中检测病原体及抗菌药物耐药性的诊断准确性,纳入74项研究共24590份样本,多数偏倚风险低。与标准表型鉴定及药敏试验相比,分子检测对革兰阴性菌、革兰阳性菌、酵母菌及耐药标志的总敏感性为92%-99%,特异性为99%-100%,支持其在临床中用于广谱病原体鉴定和耐药检测。
要点
- 分子检测鉴定革兰阴性菌、革兰阳性菌、酵母菌及耐药性的敏感性为92%-99%,特异性为99%-100%。
- 单个病原体靶标的敏感性为93%-100%,特异性为98%-100%。
- IMP和VIM碳青霉烯酶基因检测敏感性较低,分别为62%和70%。
核心结论
- 高诊断准确性支持在临床中使用分子检测鉴定广谱病原体并检测革兰阴性菌和革兰阳性菌的抗菌药物耐药性。
研究设计与样本
- 系统文献综述与荟萃分析,检索Medline、Embase、Cochrane、会议论文集及研究参考文献。
- 纳入评估市售分子检测与传统表型鉴定及药敏试验方法诊断准确性的研究,对象为阳性血培养患者。
- 共纳入74项研究、24590份样本,多数研究偏倚风险低,采用QUADAS-2评估质量。
- 采用双变量随机效应模型汇总诊断准确性,PROSPERO注册号CRD42023488057。
主要发现
- 与标准诊疗相比,分子检测鉴定总革兰阴性菌(43项研究)、革兰阳性菌(38项研究)、酵母菌(24项研究)、革兰阴性菌耐药(35项研究)、革兰阳性菌耐药(39项研究)的敏感性为92%-99%,特异性为99%-100%,阳性预测值为99%-100%,阴性预测值为97%-100%。
- 单个病原体靶标的敏感性为93%-100%,特异性为98%-100%,阳性预测值为86%-100%,阴性预测值为99%-100%。
- 7个耐药基因中5个的敏感性为91%-99%,特异性为99%-100%。
- IMP碳青霉烯酶(4项研究)敏感性为62%(95%CI 34-83%),VIM碳青霉烯酶(4项研究)敏感性为70%(95%CI 38-90%),因基因未检出或不存在于铜绿假单胞菌中(即低流行率)。
- 按地理区域(欧洲、北美、东亚)分组时,分子检测检测耐药性的性能总体相当。
关键数值与推荐
- 总革兰阴性菌、革兰阳性菌、酵母菌、革兰阴性菌耐药、革兰阳性菌耐药的汇总敏感性为92%-99%,特异性为99%-100%,阳性预测值99%-100%,阴性预测值97%-100%。
- 单个病原体靶标汇总敏感性93%-100%,特异性98%-100%,阳性预测值86%-100%,阴性预测值99%-100%。
- 7个耐药基因中5个敏感性91%-99%,特异性99%-100%。
- IMP碳青霉烯酶敏感性62%(95%CI 34-83%),VIM碳青霉烯酶敏感性70%(95%CI 38-90%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rapid identification of bloodstream pathogens and associated antimicrobial resistance (AMR) profiles by molecular tests from positive blood cultures (PBCs) have the potential to improve patient management and clinical outcomes. OBJECTIVES: A systematic review and meta-analysis were conducted to evaluate diagnostic test accuracy (DTA) of molecular tests from PBCs for detecting pathogens and AMR in the clinical setting. DATA SOURCES: Medline, Embase, Cochrane, conference proceedings, and study bibliographies were searched. STUDY ELIGIBILITY CRITERIA: Studies evaluating DTA of commercially available molecular tests vs. traditional phenotypic identification and susceptibility testing methods in patients with PBCs were eligible. PARTICIPANTS: Patients with PBCs. TESTS: Commercially available molecular tests. REFERENCE STANDARD: Traditional phenotypic identification and susceptibility testing methods (standard of care, SOC). ASSESSMENT OF RISK OF BIAS: Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies-2. METHODS OF DATA SYNTHESIS: Summary DTA outcomes were estimated using bivariate random-effects models for gram-negative bacteria (GNB), gram-positive bacteria (GPB), yeast, GNB-AMR, GPB-AMR, and specific targets when reported by ≥ 2 studies (PROSPERO CRD42023488057). RESULTS: Seventy-four studies including 24 590 samples were analysed, most of which had a low risk of bias. When compared with SOC, molecular tests showed 92-99% sensitivity, 99-100% specificity, 99-100% positive predictive value, and 97-100% negative predictive value for identifying total GNB (43 studies), GPB (38 studies), yeast (24 studies), GNB-AMR (35 studies), and GPB-AMR (39 studies). For individual pathogen targets, 93-100% sensitivity, 98-100% specificity, 86-100% positive predictive value, and 99-100% negative predictive value were estimated. Five of seven AMR genes had 91-99% sensitivity and 99-100% specificity. Sensitivity was lower for IMP (four studies; 62%; 95% CI, 34-83%) and VIM (four studies; 70%; 95% CI, 38-90%) carbapenemases, where genes were not detected or were not harboured in Pseudomonas aeruginosa (i.e. low prevalence). Performance of molecular tests in detecting AMR was generally comparable when grouped by geographical region (Europe, North America, and East Asia). DISCUSSION: High DTA support the use of molecular tests in identifying a broad panel of pathogens and detecting AMR in GNB and GPB.
引用
- Wang Y, Lindsley K, Bleak TC, et al. Performance of molecular tests for diagnosis of bloodstream infections in the clinical setting: a systematic literature review and meta-analysis. Clin Microbiol Infect. 2024. PMID: 39672467. doi:10.1016/j.cmi.2024.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。